Drug intelligence / Profile preview

Camylofin

Development stage
Unknown
Modality
Small Molecules
Administration
Oral, Intramuscular, Intravenous
01

Overview

Camylofin is a small molecule antimuscarinic drug used primarily as an antispasmodic and smooth muscle relaxant. It exerts its effects through a dual mechanism of action: - **Anticholinergic (neurotropic) action**: Camylofin inhibits the binding of acetylcholine to muscarinic receptors, thereby reducing cholinergic stimulation of smooth muscle, though this effect is less pronounced than other classic antimuscarinics[1][6]. - **Musculotropic (direct smooth muscle) action**: Camylofin directly relaxes smooth muscle by inhibiting phosphodiesterase type IV, leading to increased cyclic AMP and reduced cytosolic calcium levels. This results in effective relief from spasms[1][6][8]. Camylofin is indicated for the treatment of abdominal pain due to intestinal colic, biliary colic, renal colic, dysmenorrhoea (painful menstruation), peptic ulcer disease, chronic gastrointestinal spasm disorders, and as an adjunct in obstetrics for cervical dilation during labor[3][5][7][8]. It does not interfere with uterine contractility due to its selectivity for phosphodiesterase IV isoenzyme[6][8]. The drug can be administered orally (tablet or syrup) or via injection (intramuscular or intravenous)[7].

Other names
acamylophenine
02

Targets

mAChR (Muscarinic acetylcholine receptors)PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on Camylofin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Camylofin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call